Chronic Persistent Vascular Facial Erythema Clinical Trial
Official title:
A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel (5 mg/g Brimonidine Tartrate) in Patients With Chronic Persistent Vascular Facial Erythema.
This study evaluates the efficacy of Mirvaso® in the treatment of chronic persistent vascular facial erythema, after 4 weeks of treatment, by the Clinician erythema assessment.
This is a multicenter, open-label trial in research participants with chronic persistent
vascular facial erythema. All eligible research participants will receive Mirvaso® gel once
daily for 4 weeks, and then will be followed-up for another 2 weeks.
The study will include 4 clinical visits: before Day 1, on Day 1, Day 29 and Week 6.
Within 5 days before Day 1, the research participant will have a screening visit for
confirmation of eligibility.
On Day 1 and on Day 29, the research participant will have Mirvaso® gel applied, at the
research site, and the evaluation will be conducted before application and 3 hours after
application; During Days 2-28, research participants will have Mirvaso® gel applied once
daily, at home; On Week 6, the research participants will go back to the research site for
evaluation. No Mirvaso® gel will be applied after the visit on Day 29; Unscheduled visits
may be performed during the trial for any safety reason.
;